Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm Inc. today announced that OLEPTRO(TM) (trazodone hydrochloride extended-release tablets), a novel once-daily formulation of the antidepressant trazodone, has been launched in the United States by its joint venture with Gruppo Angelini, Angelini Labopharm. OLEPTRO(TM) is indicated for the treatment of major depressive disorder (MDD) in adults. The efficacy of OLEPTRO(TM) has been established in a trial of outpatients with MDD as well as in trials with the immediate release formulation of trazodone.

11 Aug 2010

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Alexza to raise $18.0M in registered direct offering

Alexza Pharmaceuticals, Inc. today announced that it has entered into definitive agreements with a select group of institutional investors to raise approximately $18.0 million in gross proceeds in a registered direct offering through the sale of common stock and warrants. The Company agreed to sell a total of 6,685,183 units, each unit consisting of (i) one share of common stock and (ii) one warrant to purchase 0.5 of a share of common stock, at a purchase price of $2.70 per unit.

5 Aug 2010

Long-term exposure to valproate leads to bone loss: Study

Scientists are reporting a possible explanation for the bone loss that may occur following long-term use of a medicine widely used to treat epilepsy, bipolar disorder, and other conditions. The drug, valproate, appears to reduce the formation of two key proteins important for bone strength, they said. Their study, which offers a solution to a long-standing mystery, appears in ACS' monthly Journal of Proteome Research.

5 Aug 2010

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

A single intravenous dose of the anesthetic agent ketamine appears to reduce symptoms of depression within 40 minutes among those with bipolar disorder who have not responded to other treatments, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Aug 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.

30 Jul 2010

NARSAD to honor five young scientists at Annual Klerman and Freedman Awards event

July 30 NARSAD will honor five outstanding researchers at the Annual Klerman and Freedman Awards event in New York City.

29 Jul 2010

Alexza second-quarter net loss decreases to $12.9 million

Alexza Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2010 and provided a business update. The net loss for the three and six months ended June 30, 2010, as reported in accordance with accounting principles generally accepted in the United States (GAAP), was $12.9 million and $26.3 million, respectively, compared to a net loss of $17.0 million and $23.9 million in the respective comparable periods in 2009. Alexza had consolidated cash, cash equivalents and marketable securities at June 30, 2010 of $41.7 million.

27 Jul 2010

Valproic acid halts vision loss in patients with retinitis pigmentosa

Researchers at the University of Massachusetts Medical School believe they may have found a new treatment for retinitis pigmentosa, a severe neurodegenerative disease of the retina that ultimately results in blindness. One of the more common retinal degenerative diseases, RP is caused by the death of photoreceptor cells and affects 1 in 4,000 people in the United States. RP typically manifests in young adulthood as night blindness or a loss of peripheral vision and in many cases progresses to legal blindness by age 40.

22 Jul 2010

Impact of circadian dysregulation on mental, physical health

Circadian (daily) rhythms are found in all functions - e.g. performance, mood, endocrine rhythms, behaviour, sleep timing. The biological clocks that control circadian rhythms are based on a genetic programme of interacting molecules in cells throughout the body, coordinated by a ´master clock´ in the brain and synchronised by external cues, mainly light.

16 Jul 2010

Penn researchers reverse cognitive decline in fruit flies with Alzheimer's gene mutation

Investigators have found that fruit fly (Drosophila melanogaster) males -- in which the activity of an Alzheimer's disease protein is reduced by 50 percent -- show impairments in learning and memory as they age. What's more, the researchers were able to prevent the age-related deficits by treating the flies with drugs such as lithium, or by genetic manipulations that reduced nerve-cell signaling.

16 Jul 2010

Memoir traces lifelong, undetected bipolar disorder

When Jerry Jewler turned 60, he celebrated his "coming of age" with a splashy party -- and a glorious high. The next day, he awoke to a hell he had never known: sad and depressed, unable to make even idle chatter with his houseguests, and angry at the world.

13 Jul 2010

Texas doctors bristle at Medicaid cuts as Congress to consider extending funds; State pinpoints high prescribing docs

Despite states' warnings that they will face massive budget cuts without help from Washington, Congress has not yet moved to provide $24.2 billion in additional Medicaid funding that many statehouses had anticipated would be included in a failed June bill, American Medical News reports. "Lawmakers return to Washington from their Independence Day break on July 12, but Democratic leaders have not offered a clear path forward on the issue" (Trapp, 7/12).

13 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Merck announced that the Committee for Medicinal Products for Human Use adopted a positive opinion on the pending Marketing Authorization Application for SYCREST (asenapine) sublingual tablets. The CHMP has recommended that the European Commission grant a marketing authorization for SYCREST for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. The CHMP did not support an indication for the treatment of schizophrenia.

25 Jun 2010

esperanza Magazine's feature article Marriage Matters wins 2010 MHA Media Award

esperanza Magazine's feature article "Marriage Matters" has won a Mental Health America 2010 Media Award in the national magazine category. esperanza Magazine was among 15 media outlets honored by MHA at an awards luncheon held June 12 during the advocacy organization's 2010 annual conference in Washington, DC. The awards honor excellence in reporting and portrayals of mental health issues.

19 Jun 2010

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

An assessment of patients with adult Tourette syndrome (TS) to identify clinical factors that contribute to psychosocial and occupational disabilities resulting from the vocal or motor tics that define TS found that anxiety/panic disorder may be the most disabling psychiatric condition associated with the disorder.

18 Jun 2010

Possible mechanism identified for how lithium treats bipolar disorder

Lithium has been established for more than 50 years as one of the most effective treatments for manic depression, clinically termed bipolar disorder. However, scientists have never been entirely sure exactly why it is beneficial.

18 Jun 2010

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

An emerging arm of molecular biology is introducing a new interpretation of traditional concepts of human disease, explains an article published today in Nature. According to author Dr. Arturas Petronis at the Centre for Addiction and Mental Health, the emerging science of epigenetics is offering new insights at the crossroads of genes and the environment, or nature and nurture. Dr. Petronis is head of the Krembil Family Epigenetics Laboratory at CAMH and an international expert in the field.

11 Jun 2010

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Alexza to raise $18.0M in registered direct offering

Long-term exposure to valproate leads to bone loss: Study

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

NARSAD to honor five young scientists at Annual Klerman and Freedman Awards event

Alexza second-quarter net loss decreases to $12.9 million

Valproic acid halts vision loss in patients with retinitis pigmentosa

Impact of circadian dysregulation on mental, physical health

Penn researchers reverse cognitive decline in fruit flies with Alzheimer's gene mutation

Memoir traces lifelong, undetected bipolar disorder

Texas doctors bristle at Medicaid cuts as Congress to consider extending funds; State pinpoints high prescribing docs

Shire receives FDA approval of Daytrana for ADHD in adolescents

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

esperanza Magazine's feature article Marriage Matters wins 2010 MHA Media Award

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

Possible mechanism identified for how lithium treats bipolar disorder

Emerging science of epigenetics offers new insights at crossroads of genes and the environment: Article

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Bipolar Disorder News and Research

Latest Bipolar Disorder News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in